Compassionate Use of Osocimab in Preventing Thrombotic Complications Without Incremental Bleeding: A Case Report

Abstract

Objective

To describe an innovative anticoagulation strategy in a 20-year-old woman with innate jejunal atresia and ultrashort bowel syndrome who was dependent on long-term parenteral nutrition and suffered from multiple venous thrombotic events and bleeding complications since infancy.

Design

Single-patient case report.

Setting

Dresden University Hospital, Dresden, Germany.

Patient

Being fully CVC-dependent since birth, our patient repeatedly developed catheter-related thrombosis (CRT) since infancy and was treated with daily low-molecular-weight heparin injections for more than 15 years. Despite this, clotting, severe gastrointestinal bleeding, and osteoporosis remained a persistent problem, causing numerous hospitalizations over the years, significant developmental delays, and a decline in the patient's body mass index (BMI). A short period of rivaroxaban treatment had to be stopped owing to acute gastrointestinal bleeding. After the failure of all approved anticoagulant concepts, compassionate use access was granted to the investigational drug osocimab, a human monoclonal antibody inhibitor of factor XIa. Hereditary FXI deficiency as well as FXI inhibition in animal models have been shown to reduce arterial and venous thrombosis without increasing bleeding. Consistent with this, short-term osocimab treatment has shown clinical efficacy in preventing postoperative venous thromboembolism after knee replacement surgery and in reducing dialysis conduit clotting compared with placebo in patients undergoing hemodialysis, without increasing the rate of clinically relevant bleeding versus comparators. After initiating osocimab, the patient experienced no further clotting complications, and bleeding decreased in frequency and severity. The patient's BMI decline immediately stopped; her weight increased by over 10% in the subsequent 20 months, and menstruation started 3 months later without signs of menorrhagia. Now, with 2.5 years of uninterrupted exposure outside of a clinical trial, this patient has experienced the longest duration of factor XIa inhibition to date. She continues to receive osocimab under the compassionate use program and maintains a positive change in her well-being and quality of life.

Keywords

anticoagulation - catheter-related thrombosis - factor Xia - gastrointestinal bleeding - parenteral feeding - osocimab

Publikationsverlauf

Eingereicht: 23. Januar 2025

Angenommen: 30. März 2025

Accepted Manuscript online:
09. April 2025

Artikel online veröffentlicht:
06. Mai 2025

• References

• 1 Best KE, Tennant PW, Addor MC. et al. Epidemiology of small intestinal atresia in Europe: a register-based study. Arch Dis Child Fetal Neonatal Ed 2012; 97 (05) F353-F358
• 2 Kirtane JM, Bhange SA, Nabi F, Shah V. Duodenal atresia with familial apple peel syndrome: case study with review of literature. BMJ Case Rep 2019; 12 (08) e230160
• 3 Digilio MC, Magliozzi M, Di Pede A. et al. Familial aggregation of “apple peel” intestinal atresia and cardiac left-sided obstructive lesions: a possible causal relationship with NOTCH1 gene mutations. Am J Med Genet A 2019; 179 (08) 1570-1574
• 4 Stollman TH, de Blaauw I, Wijnen MH. et al. Decreased mortality but increased morbidity in neonates with jejunoileal atresia; a study of 114 cases over a 34-year period. J Pediatr Surg 2009; 44 (01) 217-221
• 5 Festen S, Brevoord JC, Goldhoorn GA. et al. Excellent long-term outcome for survivors of apple peel atresia. J Pediatr Surg 2002; 37 (01) 61-65
• 6 Coletta R, Mussi E, Uccheddu F, Volpe Y, Morabito A. Preoperative planning of spiral intestinal lengthening and tailoring: a geometrical approach. Bioengineering (Basel) 2021; 8 (02) 20
• 7 Gajic-Veljanoski O, Phua CW, Shah PS, Cheung AM. Effects of long-term low-molecular-weight heparin on fractures and bone density in non-pregnant adults: a systematic review with meta-analysis. J Gen Intern Med 2016; 31 (08) 947-957
• 8 Johnson E, Vu L, Matarese LE. Bacteria, bones, and stones: managing complications of short bowel syndrome. Nutr Clin Pract 2018; 33 (04) 454-466
• 9 Katz S, Weinerman S. Osteoporosis and gastrointestinal disease. Gastroenterol Hepatol (N Y) 2010; 6 (08) 506-517
• 10 Schaefer M, Buchmueller A, Dittmer F, Straßburger J, Wilmen A. Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI. J Mol Biol 2019; 431 (24) 4817-4833
• 11 Preis M, Hirsch J, Kotler A. et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 2017; 129 (09) 1210-1215
• 12 Salomon O, Seligsohn U. New observations on factor XI deficiency. Haemophilia 2004; 10 (Suppl. 04) 184-187
• 13 Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111 (08) 4113-4117
• 14 Badimon JJ, Escolar G, Zafar MU. Factor XI/XIa inhibition: the arsenal in development for a new therapeutic target in cardio- and cerebrovascular disease. J Cardiovasc Dev Dis 2022; 9 (12) 9
• 15 Weitz JI, Bauersachs R, Becker B. et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA 2020; 323 (02) 130-139
• 16 Weitz JI, Tankó LB, Floege J. et al; CONVERT Investigators. Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial. Nat Med 2024; 30 (02) 435-442
• 17 World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310 (20) 2191-2194
• 18 Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Rep 2013; 2013: bcr2013201554
• 19 Geerts W. Central venous catheter-related thrombosis. Hematology (Am Soc Hematol Educ Program) 2014; 2014 (01) 306-311
• 20 Zaccone V, Santoro L, Guerrieri E. et al. Prevention and treatment of catheter-related venous thrombosis in long-term parenteral nutrition: a SINuC position statement. Front Nutr 2023; 10: 1106327
• 21 Smith RW, Pettini M, Gulden R, Wendel D. Central venous catheter safety in pediatric patients with intestinal failure. Nutr Clin Pract 2023; 38 (06) 1273-1281
• 22 Johansen M, Classen V, Muchantef K. Long-term IV access in paediatrics - why, what, where, who and how. Acta Anaesthesiol Scand 2021; 65 (03) 282-291
• 23 Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI. Medical device-induced thrombosis: what causes it and how can we prevent it?. J Thromb Haemost 2015; 13 (Suppl. 01) S72-S81
• 24 Pfeffer MA, Kohs TCL, Vu HH. et al. Factor XI inhibition for the prevention of catheter-associated thrombosis in patients with cancer undergoing central line placement: a phase 2 clinical trial. Arterioscler Thromb Vasc Biol 2024; 44 (01) 290-299